You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).

Figure INF-10:  Prevalence of markers of HBV infection estimated among national and sub-national samples of injecting drug users 2003 to 2004, where data are available – Part (ii) Percentage positive for aHBc (ever infected) – map of EU

Figure INF-10 part ii

Notes:

Figures in (brackets) are local data. Colour indicates midpoint of national data, or if not available, of local data.

Data for Portugal include non-injectors and are likely to underestimate prevalence in injectors.

Data for The Netherlands are 1999-2000.

*Data for Italy and Austria are not prevalence of aHBc but prevalence of 'all HBV markers' as a proxy of aHBc prevalence.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points. For primary sources, study details and data before 2003, see Table INF-14.